Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naluzotan in Generalized Anxiety Disorder
NCT00248183Phase 3Completed
- Sponsor
- Epix Pharmaceuticals
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in generalized anxiety disorder (GAD) comparing PRX-00023 with Placebo (2 arms). Primary endpoint: Hamilton Anxiety Rating Scale at 8 weeks. Started Aug 2005; status: completed.
02
Drugs
naluzotan
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00248183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00248183.